Clinical trials: MEASLES DISEASE
Prophylaxis for the Measles Infection
A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV by SoloventTM device or licensed measles…
- Trial name
- PMV-001 (NCT01557699)
- Testing
- PMV via Puffhaler® device, PMV via SoloventTM device, Licensed Subcutaneous Measles Vaccine
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles, Rubella
Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
This is an open-label, randomized, 2-arm clinical trial in healthy infants in Bangladesh. The primary purpose of the study is to assess the immunogenicity of measles-rubella (MR) vaccine when delivered at 6 months.
- Conditions
- Measles, Rubella, Rubella Syndrome, Congenital
- Trial name
- NCT03071575
- Testing
- Measles-rubella (MR) vaccine at 6 months of age, Measles-rubella (MR) vaccine at 9 months of age
- Where
- Bangladesh
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Verruca Viral
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a maximum incidence between 12 and…
- Trial name
- MMR (NCT04428359)
- Testing
- Measles-Mumps-Rubella Vaccine, Vit D
- Where
- Nepal
- Volunteers
- 66 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Measles, Mumps
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for…
- Conditions
- Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT01681992
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 81 sites in United States, Czechia and 5 more
- Volunteers
- 4,538 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles/Rubella
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
The purpose of this survey is to assess the safety of freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine…
- Trial name
- NCT02158364
- Testing
- Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
- Where
- Japan
- Volunteers
- 3,331 people
- Sponsor
- Takeda
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
The primary study objectives are: To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00566527
- Testing
- ProQuad® manufactured with recombinant Human Albumin (rHA)
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
The purpose of this study is to determine the clinical efficacy of MV-NIS (measles virus-sodium iodide symporter) therapy for people with relapsed/refractory myeloma when given with cyclophosphamide
- Trial name
- NCT02192775
- Testing
- MV-NIS
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arkansas
Malaria, Malaria Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6…
- Trial name
- NCT02699099
- Testing
- Vitamin A, Candidate Plasmodium falciparum malaria vaccine, MR-Vac
- Where
- 2 sites in Ghana
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis A Virus
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
Hepatitis A vaccine will be given either alone or together with measles, mumps, rubella, and varicella vaccine and pneumococcal 7-valent conjugate vaccine at the first dose and together with measles, mumps, rubella, and varicella…
- Trial name
- NCT00312858
- Testing
- Comparator: VAQTA™ (Hepatitis A vaccine), Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00985166
- Testing
- ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live), Comparator: M-M-R II, Comparator: Varivax
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Meningitis, Measles
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
This is a Phase III, modified single-blind, randomized, parallel-group, multicenter, comparative trial in the United States designed to evaluate the immunogenicity and safety of two doses of Menactra vaccine administered alone…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00384397
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 39 sites in United States
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles, Mumps
ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00975507
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, Comparator: M-M-R II
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Recurrent Glioblastoma
- Trial name
- NCT00390299
- Testing
- Carcinoembryonic Antigen-Expressing Measles Virus, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Measles, Mumps
A Study of ProQuad™ in Healthy Children in Korea (V221-023)
This study will compare ProQuad™ and concomitant administration of M-M-R™ II and Varivax™ with respect to immunogenicity, safety and tolerability.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00839917
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™), M-M-R™ II and Varivax™
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Tetanus, Diphtheria
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
The study was designed to compare the safety and immunogenicity of DTap-IPV with DAPTACEL® + IPOL® as the 5th dose booster in children ≥ 4 to < 7 years of age in the US and Puerto Rico who were previously vaccinated with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Measles
- Trial name
- NCT01346293
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 3,372 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent)…
- Trial name
- NCT00450814
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic